Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL) mutant lung cancers are particularly aggressive, lack PD-L1, and respond poorly to immune checkpoint blockade (ICB). The mechanistic basis f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Kitajima, Shunsuke, Ivanova, Elena, Guo, Sujuan, Yoshida, Ryohei, Campisi, Marco, Sundararaman, Shriram K., Tange, Shoichiro, Mitsuishi, Yoichiro, Thai, Tran C., Masuda, Sayuri, Piel, Brandon P., Sholl, Lynette M., Kirschmeier, Paul T., Paweletz, Cloud P., Watanabe, Hideo, Yajima, Mamiko, Barbie, David A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328329/
https://ncbi.nlm.nih.gov/pubmed/30297358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0689
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi